MBMA data curation: How AI and expert meta-analysts get it right, fast

Ask people what makes model-based meta-analysis (MBMA) powerful and most will point to the models. The dose-response curves, the longitudinal trends, the prediction about a trial nobody has run yet. That’s the exciting part, and it’s where the science gets to show off. But talk to anyone who has delivered an MBMA and they’ll tell you the models are rarely what slows a project down. The data is. MBMA is, at its core, a rigorous form of evidence synthesis in clinical research, and the step that decides whether it works is MBMA data curation.

Every MBMA starts with published clinical studies. Sometimes there are dozens. Sometimes there are hundreds. Every study reports outcomes a little differently, measures patients at different timepoints, and includes different populations. Before anyone can build a model, all of that evidence has to be turned into one dataset that compares like with like. That has always been the hardest part.

The bottleneck nobody puts on the slide

Curating the data MBMA needs is slow, careful work, and it is clinical data curation at its most demanding. Someone has to find the relevant studies, read them, and pull out the numbers that matter: response rates, dosing, follow up, endpoint definitions, population characteristics, all of it. Then it has to be harmonized, so a five-point improvement in one trial means the same thing as a five-point improvement in another. Those small mistakes don’t stay small. They carry all the way through to the final decision.

Think about rheumatoid arthritis. One study reports ACR50 after 12 weeks. Another reports ACR70 after 24 weeks. Another includes patients taking methotrexate while another does not. This is where MBMA data curation differs from a traditional meta-analysis: before those studies can be compared, someone has to model and reconcile all of those differences, not just pool them.

Where AI earns its place in MBMA data curation

This is exactly where AI has changed the math. Modern AI tools can read through the literature and organize the evidence much faster than a team working by hand. What used to take weeks can now be done in a fraction of the time.

The catch is that speed on its own isn’t the goal. An analysis built on data that was assembled quickly but wrongly is worse than no analysis at all, because it looks authoritative while pointing in the wrong direction. So the real question was never whether AI could do the extraction. It was how you keep it trustworthy while it does.

In my view, data quality is among the most important considerations. MBMA requires highly specific datasets to ensure accuracy. AI can accelerate the creation of those datasets, but validation workflows are critical. We use a human review process, so experts review and adjudicate the AI’s predictions before anything is used.

That last part is the whole game. The AI does the heavy lifting of finding and structuring the evidence. Experienced meta-analysts review what it produces, catch the edge cases, and sign off before any of it reaches a model. Fast and careful, rather than one at the expense of the other.

What that looks like at Certara

At Certara, AI helps us find and organize the evidence faster. Our CODEX clinical outcomes databases provide the foundation, and our meta-analysts review every dataset before it is used. AI speeds up the work. Our scientists make sure every dataset is accurate.

Building a validated evidence base for your indication is exactly what Certara’s MBMA experts and the CODEX outcomes databases are built for. Talk with our MBMA team to see how it can support your next development decision.

The result is that the data layer stops being the bottleneck and starts being an advantage. Teams spend less time building the dataset and more time answering the questions that matter. Sponsors can make better-informed development decisions earlier, before committing the time and cost of another clinical trial. Which dose should move forward? How does a therapy compare with competitors? What does the next trial need to show?

Why the data layer decides everything downstream

It’s tempting to treat data curation as plumbing, the unglamorous step you get through on the way to the interesting analysis. But in MBMA the quality of that plumbing sets the ceiling on everything that follows. A carefully built dataset lets a team compare therapies on a consistent basis, construct credible external comparators, and design a smarter next trial. A shaky one undermines all of that, no matter how sophisticated the model sitting on top of it. Strong evidence synthesis is what separates a defensible comparison from a misleading one.

Getting the data right, and getting it right quickly, is what lets MBMA do its real job: helping teams make confident decisions before they commit serious money.

The quiet edge

The models will always get the attention, and they should. But the edge in modern MBMA is increasingly in the layer underneath, where AI and human judgment work together to turn a messy published record into evidence you can actually trust. AI helps people get through the repetitive work faster. Scientists bring the experience to know when something isn’t right. That combination is what makes modern MBMA stronger than either one on its own.

Want to move faster without cutting corners on data quality? Talk with our MBMA team.